advanced colorectal cancer
Conditions
Interventions
Ttreatment group:Thalidomide
Control group:None
Sponsors
Fujian Cancer Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with advanced colorectal adenocarcinoma confirmed by pathology or clinical diagnosis; 2. Aged 18 to 75 years; 3. There are measurable target lesions; 4. Progression after standard second-line treatment (used irinotecan, oxaliplatin, capecitabine or fluorouracil), oral trifluridine tippiridine treatment; 5. According to the Eastern Cooperative Oncology Group (ECOG) quality of life score of 0 to 2; 6. Expected survival period >= 3 months; 7. Women of childbearing age need a negative pregnancy test; 8. Combined with a small amount of ascites, no obvious symptoms and no clinical intervention; 9. There is no contraindication to chemotherapy in basic examinations such as electrocardiogram, blood, and biochemistry; 10. Patients with known MSI-H but unable to tolerate or afford the cost of immunotherapy and willing to enroll after fully informed.
Exclusion criteria
Exclusion criteria: 1. No reliable contraceptive measures during reproductive period; 2. Patients with gastrointestinal obstruction; 3. Those with a history of thromboembolism, except for thrombosis caused by PICC; 4. Those who are known to be allergic to thalidomide/trifluridine tippiridine tablets; 5. Trifluridine tippiridine tablets have been used in previous treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| toxic and side effect;overall survival;progression-free survival;objective remission rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactGuo Zengqing
Fujian Medical University Cancer Hospital, Fujian Cancer Hospital
Outcome results
None listed